Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert Wayne Yeh, M.D.

Concepts

This page shows the publications Robert Yeh has written about Humans.
Connection Strength

1.800
  1. Long-term safety of drug-coated devices for peripheral revascularisation. EuroIntervention. 2021 Sep 20; 17(7):590-598.
    View in: PubMed
    Score: 0.011
  2. Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries. EuroIntervention. 2021 Aug 06; 17(5):e380-e387.
    View in: PubMed
    Score: 0.011
  3. Cardiovascular Deaths During the COVID-19 Pandemic in the United States. J Am Coll Cardiol. 2021 01 19; 77(2):159-169.
    View in: PubMed
    Score: 0.011
  4. Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study: Findings From the EXTEND-DAPT Study. Circ Cardiovasc Qual Outcomes. 2021 01; 14(1):e006589.
    View in: PubMed
    Score: 0.011
  5. Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: A systematic review and meta-analysis. Catheter Cardiovasc Interv. 2021 03; 97(4):569-578.
    View in: PubMed
    Score: 0.011
  6. Evaluation of Hospital Performance Using the Excess Days in Acute Care Measure in the Hospital Readmissions Reduction Program. Ann Intern Med. 2021 01; 174(1):86-92.
    View in: PubMed
    Score: 0.011
  7. Revascularization Practices and Outcomes in Patients With Multivessel Coronary Artery Disease Who Presented With Acute Myocardial Infarction and Cardiogenic Shock in the US, 2009-2018. JAMA Intern Med. 2020 10 01; 180(10):1317-1327.
    View in: PubMed
    Score: 0.011
  8. Use of etomidate in patients with heart failure undergoing noncardiac surgery. Br J Anaesth. 2020 12; 125(6):943-952.
    View in: PubMed
    Score: 0.011
  9. A Simple Formula to Estimate Parathyroid Weight on 4D-CT, Predict Pathologic Weight, and Diagnose Parathyroid Adenoma in Patients with Primary Hyperparathyroidism. AJNR Am J Neuroradiol. 2020 09; 41(9):1690-1697.
    View in: PubMed
    Score: 0.011
  10. Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. Circulation. 2020 07 21; 142(3):306-308.
    View in: PubMed
    Score: 0.010
  11. Validation of Administrative Claims to Ascertain Outcomes in Pivotal Trials of Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2020 08 10; 13(15):1777-1785.
    View in: PubMed
    Score: 0.010
  12. Prevalence of angina and use of medical therapy among US adults: A nationally representative estimate. Am Heart J. 2020 10; 228:44-46.
    View in: PubMed
    Score: 0.010
  13. Mitral Valve Surgical Volume and Transcatheter Mitral Valve Repair Outcomes: Impact of a Proposed Volume Requirement on Geographic Access. J Am Heart Assoc. 2020 06 02; 9(11):e016140.
    View in: PubMed
    Score: 0.010
  14. Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement: Findings From the EXTEND Study. Circulation. 2020 07 21; 142(3):203-213.
    View in: PubMed
    Score: 0.010
  15. Weighing the potential late benefits versus early hazard associated with bioresorbable vascular scaffolds in percutaneous coronary interventions: a Markov decision analytic model. Coron Artery Dis. 2020 05; 31(3):230-236.
    View in: PubMed
    Score: 0.010
  16. Quality Measure Development and Associated Spending by the Centers for Medicare & Medicaid Services. JAMA. 2020 04 28; 323(16):1614-1616.
    View in: PubMed
    Score: 0.010
  17. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative. Circ Cardiovasc Qual Outcomes. 2020 03; 13(3):e006275.
    View in: PubMed
    Score: 0.010
  18. The DAPT Score Uncouples Bleeding and Ischemic Risk…Again. JACC Cardiovasc Interv. 2020 03 09; 13(5):647-650.
    View in: PubMed
    Score: 0.010
  19. Short DAPT duration after ACS - not for the faint of heart. EuroIntervention. 2019 Dec 06; 15(11):e943-e944.
    View in: PubMed
    Score: 0.010
  20. Relative Effects of the Hospital Readmissions Reduction Program on Hospitals That Serve Poorer Patients. Med Care. 2019 12; 57(12):968-976.
    View in: PubMed
    Score: 0.010
  21. Thirty-Day Spending and Outcomes for an Episode of Pneumonia Care Among Medicare Beneficiaries. Chest. 2020 05; 157(5):1241-1249.
    View in: PubMed
    Score: 0.010
  22. Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement: Findings From the EXTEND Study. Circ Cardiovasc Interv. 2019 11; 12(11):e008231.
    View in: PubMed
    Score: 0.010
  23. Association of Frailty With 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia Among Elderly Adults. JAMA Cardiol. 2019 11 01; 4(11):1084-1091.
    View in: PubMed
    Score: 0.010
  24. Myocardial Perfusion After Coronary Chronic Total Occlusion Percutaneous Coronary Intervention: Does It Matter to Myocytes How You Cross the Lesion? Circ Cardiovasc Interv. 2019 11; 12(11):e008568.
    View in: PubMed
    Score: 0.010
  25. Geographic Patterns of Growth for Transcatheter Aortic Valve Replacement in the United States. Circulation. 2019 09 10; 140(11):969-971.
    View in: PubMed
    Score: 0.010
  26. Examining the Operator Learning Curve for Percutaneous Coronary Intervention of Chronic Total Occlusions. Circ Cardiovasc Interv. 2019 08; 12(8):e007877.
    View in: PubMed
    Score: 0.010
  27. Hospital revisits within 30 days after discharge for medical conditions targeted by the Hospital Readmissions Reduction Program in the United States: national retrospective analysis. BMJ. 2019 08 12; 366:l4563.
    View in: PubMed
    Score: 0.010
  28. Readmission Penalties: The Authors Reply. Health Aff (Millwood). 2019 08; 38(8):1410.
    View in: PubMed
    Score: 0.010
  29. Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort. Eur Heart J. 2019 07 14; 40(27):2231-2239.
    View in: PubMed
    Score: 0.010
  30. Trends in isolated aortic valve replacement in the United States in the early phase of expansion of TAVR. Int J Cardiol. 2019 10 01; 292:68-72.
    View in: PubMed
    Score: 0.010
  31. Health Insurance and Mobile Health Devices: Opportunities and Concerns. JAMA. 2019 May 14; 321(18):1767-1768.
    View in: PubMed
    Score: 0.010
  32. Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention. Coron Artery Dis. 2019 05; 30(3):177-182.
    View in: PubMed
    Score: 0.010
  33. Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices. JAMA Cardiol. 2019 04 01; 4(4):332-340.
    View in: PubMed
    Score: 0.010
  34. Patient Readmission Rates For All Insurance Types After Implementation Of The Hospital Readmissions Reduction Program. Health Aff (Millwood). 2019 04; 38(4):585-593.
    View in: PubMed
    Score: 0.010
  35. Public Reporting of Percutaneous Coronary Intervention Outcomes: Institutional Costs and Physician Burden. J Am Coll Cardiol. 2019 05 28; 73(20):2604-2608.
    View in: PubMed
    Score: 0.010
  36. Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention: The OPEN-CTO Registry. JACC Cardiovasc Interv. 2019 04 08; 12(7):651-658.
    View in: PubMed
    Score: 0.010
  37. Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study. Am Heart J. 2019 06; 212:64-71.
    View in: PubMed
    Score: 0.010
  38. Extracorporeal Membrane Oxygenation Use in Cardiogenic Shock: Impact of Age on In-Hospital Mortality, Length of Stay, and Costs. Crit Care Med. 2019 03; 47(3):e214-e221.
    View in: PubMed
    Score: 0.009
  39. Drug-Eluting Stent Implantation and Long-Term Survival Following Peripheral Artery Revascularization. J Am Coll Cardiol. 2019 05 28; 73(20):2636-2638.
    View in: PubMed
    Score: 0.009
  40. Temporal Trends in Unstable Angina Diagnosis Codes for Outpatient Percutaneous Coronary Interventions. JAMA Intern Med. 2019 02 01; 179(2):259-261.
    View in: PubMed
    Score: 0.009
  41. Contemporary Use and Trends in Unprotected Left Main Coronary Artery Percutaneous Coronary Intervention in the United States: An Analysis of the National Cardiovascular Data Registry Research to Practice Initiative. JAMA Cardiol. 2019 02 01; 4(2):100-109.
    View in: PubMed
    Score: 0.009
  42. Association of Physician Variation in Use of Manual Aspiration Thrombectomy With Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: The National Cardiovascular Data Registry CathPCI Registry. JAMA Cardiol. 2019 02 01; 4(2):110-118.
    View in: PubMed
    Score: 0.009
  43. Reply: Trends in Isolated Surgical Aortic Valve Replacement. JACC Cardiovasc Interv. 2019 01 14; 12(1):108-109.
    View in: PubMed
    Score: 0.009
  44. SCOT-HEART: Does it live up to the PROMISE? J Cardiovasc Comput Tomogr. 2019 May - Jun; 13(3):48-50.
    View in: PubMed
    Score: 0.009
  45. Association of Hospital Surgical Aortic Valve Replacement Quality With 30-Day and 1-Year Mortality After Transcatheter Aortic Valve Replacement. JAMA Cardiol. 2019 01 01; 4(1):16-22.
    View in: PubMed
    Score: 0.009
  46. Hospital Variation in the Utilization of Short-Term Nondurable Mechanical Circulatory Support in Myocardial Infarction Complicated by Cardiogenic Shock. Circ Cardiovasc Interv. 2019 01; 12(1):e007270.
    View in: PubMed
    Score: 0.009
  47. Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia. JAMA. 2018 12 25; 320(24):2542-2552.
    View in: PubMed
    Score: 0.009
  48. Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. BMJ. 2018 Dec 13; 363:k5094.
    View in: PubMed
    Score: 0.009
  49. Re: Multivessel Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction with Cardiogenic Shock. Epidemiology. 2018 11; 29(6):e59-e60.
    View in: PubMed
    Score: 0.009
  50. Patient-Reported Outcomes in Cardiology. Circ Cardiovasc Qual Outcomes. 2018 11; 11(11):e004794.
    View in: PubMed
    Score: 0.009
  51. Trends in Isolated Surgical Aortic Valve Replacement According to Hospital-Based Transcatheter Aortic Valve Replacement Volumes. JACC Cardiovasc Interv. 2018 11 12; 11(21):2148-2156.
    View in: PubMed
    Score: 0.009
  52. The Value of Claims-Based Nontraditional Risk Factors in Predicting Long-term Mortality After MitraClip Procedure. Can J Cardiol. 2018 12; 34(12):1648-1654.
    View in: PubMed
    Score: 0.009
  53. Impact of a Claims-Based Frailty Indicator on the Prediction of Long-Term Mortality After Transcatheter Aortic Valve Replacement in Medicare Beneficiaries. Circ Cardiovasc Qual Outcomes. 2018 10; 11(10):e005048.
    View in: PubMed
    Score: 0.009
  54. Prevalence and Outcomes of Isolated Tricuspid Valve Surgery Among Medicare Beneficiaries. Am J Cardiol. 2019 01 01; 123(1):132-138.
    View in: PubMed
    Score: 0.009
  55. Meta-Analysis of Bleeding Risk Prediction Scores in Patients After Percutaneous Coronary Intervention on Dual Antiplatelet Therapy. Am J Cardiol. 2018 12 01; 122(11):1843-1852.
    View in: PubMed
    Score: 0.009
  56. Inadequate Surrogates for Imperfect Quality Measures. Circ Cardiovasc Interv. 2018 09; 11(9):e007216.
    View in: PubMed
    Score: 0.009
  57. Inferior Vena Cava Filters and Mortality: Is It the Underlying Process, the Patient, or the Device? JAMA Netw Open. 2018 07 06; 1(3):e180453.
    View in: PubMed
    Score: 0.009
  58. A Survey of Interventional Cardiologists' Attitudes and Beliefs About Public Reporting of Percutaneous Coronary Intervention. JAMA Cardiol. 2018 07 01; 3(7):629-634.
    View in: PubMed
    Score: 0.009
  59. Exposure Misclassification in Observational Studies: Setting New Standards. Circ Cardiovasc Qual Outcomes. 2018 07; 11(7):e004939.
    View in: PubMed
    Score: 0.009
  60. High Burden of 30-Day Readmissions After Acute Venous Thromboembolism in the United States. J Am Heart Assoc. 2018 06 26; 7(13).
    View in: PubMed
    Score: 0.009
  61. State Variation in the Use of Non-Acute Coronary Angiograms and Coronary Revascularization Procedures. JACC Cardiovasc Interv. 2018 05 14; 11(9):912-913.
    View in: PubMed
    Score: 0.009
  62. Complete vs Incomplete Revascularization During Percutaneous Coronary Intervention and Improved Survival-The Key Is Immortality. JAMA Cardiol. 2018 05 01; 3(5):443-444.
    View in: PubMed
    Score: 0.009
  63. 30-Day Episode Payments and Heart Failure Outcomes Among Medicare Beneficiaries. JACC Heart Fail. 2018 05; 6(5):379-387.
    View in: PubMed
    Score: 0.009
  64. National trends, predictors of use, and in-hospital outcomes in mechanical circulatory support for cardiogenic shock. EuroIntervention. 2018 04 06; 13(18):e2152-e2159.
    View in: PubMed
    Score: 0.009
  65. Academic Cardiology and Social Media: Navigating the Wisdom and Madness of the Crowd. Circ Cardiovasc Qual Outcomes. 2018 04; 11(4):e004736.
    View in: PubMed
    Score: 0.009
  66. Applicability of Publicly Reported Hospital Readmission Measures to Unreported Conditions and Other Patient Populations: A Cross-sectional All-Payer Study. Ann Intern Med. 2018 05 01; 168(9):631-639.
    View in: PubMed
    Score: 0.009
  67. Association Between 30-Day Episode Payments and Acute Myocardial Infarction Outcomes Among Medicare Beneficiaries. Circ Cardiovasc Qual Outcomes. 2018 03; 11(3):e004397.
    View in: PubMed
    Score: 0.009
  68. Utilization, In-Hospital Mortality, and 30-Day Readmission After Percutaneous Mitral Valve Repair in the United States Shortly After Device Approval. Am J Cardiol. 2018 06 01; 121(11):1365-1372.
    View in: PubMed
    Score: 0.009
  69. Safety and effectiveness of zotarolimus-eluting stents for percutaneous coronary intervention: a systematic review. Future Cardiol. 2018 05 01; 14(3):251-267.
    View in: PubMed
    Score: 0.009
  70. Duration of Dual Antiplatelet Therapy for Stented Patients: An Update for the Clinician. Prog Cardiovasc Dis. 2018 Jan - Feb; 60(4-5):491-499.
    View in: PubMed
    Score: 0.009
  71. Understanding How to Improve Quality and Value for Patients With Acute Myocardial Infarction. JAMA Cardiol. 2018 02 01; 3(2):102-103.
    View in: PubMed
    Score: 0.009
  72. Mortality, Length of Stay, and Cost of Weekend Admissions. J Hosp Med. 2018 07 01; 13(7):476-481.
    View in: PubMed
    Score: 0.009
  73. Challenges of Assessing Therapeutic or Diagnostic Outcomes with Observational Data. Am J Med. 2018 02; 131(2):206-210.
    View in: PubMed
    Score: 0.009
  74. Readmissions After Revascularization Procedures for Peripheral Arterial Disease: A Nationwide Cohort Study. Ann Intern Med. 2018 01 16; 168(2):93-99.
    View in: PubMed
    Score: 0.009
  75. Brachial-ankle pulse wave velocity as a marker of adverse events following non-ST-elevation myocardial infarction: a new standard in risk stratification? Coron Artery Dis. 2017 12; 28(8):634-635.
    View in: PubMed
    Score: 0.009
  76. High-Risk Percutaneous Coronary Intervention in Public Reporting States: the Evidence, Exclusion of Critically Ill Patients, and Implications. Curr Heart Fail Rep. 2017 12; 14(6):514-518.
    View in: PubMed
    Score: 0.009
  77. Should We Care About Short-Term Readmissions After Percutaneous Coronary Intervention? Circ Cardiovasc Interv. 2017 12; 10(12).
    View in: PubMed
    Score: 0.009
  78. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2017 Oct 31; 70(18):2213-2223.
    View in: PubMed
    Score: 0.009
  79. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing. Circulation. 2017 Dec 05; 136(23):2210-2219.
    View in: PubMed
    Score: 0.009
  80. Incentivizing Transradial Access for Primary Percutaneous Coronary Intervention While Maintaining Timely Reperfusion. JAMA Cardiol. 2017 10 01; 2(10):1057-1058.
    View in: PubMed
    Score: 0.009
  81. Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States. Circ Cardiovasc Qual Outcomes. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.009
  82. Public Reporting of Percutaneous Coronary Intervention Mortality in New York State: Are We Helping Our Patients? Circ Cardiovasc Qual Outcomes. 2017 09; 10(9).
    View in: PubMed
    Score: 0.009
  83. Seasonality and Readmission after Heart Failure, Myocardial Infarction, and Pneumonia. Health Serv Res. 2018 08; 53(4):2185-2202.
    View in: PubMed
    Score: 0.009
  84. Target Vessel Revascularization and Territory of Myocardial Ischemia in Patients With Chronic Total Occlusions. J Am Coll Cardiol. 2017 08 29; 70(9):1196-1197.
    View in: PubMed
    Score: 0.009
  85. Individualizing dual antiplatelet therapy duration after percutaneous coronary intervention: from randomized control trials to personalized medicine. Expert Rev Cardiovasc Ther. 2017 Sep; 15(9):681-693.
    View in: PubMed
    Score: 0.009
  86. Comparison of 30-Day Readmission Rates After Hospitalization for Acute Myocardial Infarction in Men Versus Women. Am J Cardiol. 2017 Oct 01; 120(7):1070-1076.
    View in: PubMed
    Score: 0.008
  87. Short-term rehospitalization across the spectrum of age and insurance types in the United States. PLoS One. 2017; 12(7):e0180767.
    View in: PubMed
    Score: 0.008
  88. Contemporary Drug-Eluting Stent Platforms: Design, Safety, and Clinical Efficacy. Cardiol Clin. 2017 May; 35(2):281-296.
    View in: PubMed
    Score: 0.008
  89. Management of Patients With Cardiac Arrest Complicating Myocardial Infarction in New York Before and After Public Reporting Policy Changes. Circ Cardiovasc Interv. 2017 May; 10(5).
    View in: PubMed
    Score: 0.008
  90. The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease. Expert Opin Drug Saf. 2017 May; 16(5):561-572.
    View in: PubMed
    Score: 0.008
  91. The Effect of Survivor Bias on Observational Analyses of Staged PCI in STEMI Patients. JACC Cardiovasc Interv. 2017 03 27; 10(6):629-630.
    View in: PubMed
    Score: 0.008
  92. Utilization and outcomes of transcatheter aortic valve replacement in the United States shortly after device approval. Catheter Cardiovasc Interv. 2017 Nov 01; 90(5):830-838.
    View in: PubMed
    Score: 0.008
  93. Decision Tools to Improve Personalized Care in Cardiovascular Disease: Moving the Art of Medicine Toward Science. Circulation. 2017 03 21; 135(12):1097-1100.
    View in: PubMed
    Score: 0.008
  94. New-Generation Coronary Stents: Current Data and Future Directions. Curr Atheroscler Rep. 2017 Mar; 19(3):14.
    View in: PubMed
    Score: 0.008
  95. Quality of Care at Hospitals Identified as Outliers in Publicly Reported Mortality Statistics for Percutaneous Coronary Intervention. Circulation. 2017 May 16; 135(20):1897-1907.
    View in: PubMed
    Score: 0.008
  96. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program. JACC Cardiovasc Interv. 2017 02 13; 10(3):247-254.
    View in: PubMed
    Score: 0.008
  97. Readmission Rates After Passage of the Hospital Readmissions Reduction Program: A Pre-Post Analysis. Ann Intern Med. 2017 Mar 07; 166(5):324-331.
    View in: PubMed
    Score: 0.008
  98. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. JACC Cardiovasc Interv. 2016 12 12; 9(23):2376-2386.
    View in: PubMed
    Score: 0.008
  99. Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. J Am Heart Assoc. 2016 10 17; 5(10).
    View in: PubMed
    Score: 0.008
  100. Treatment and Outcomes of Acute Myocardial Infarction Complicated by Shock After Public Reporting Policy Changes in New York. JAMA Cardiol. 2016 09 01; 1(6):648-54.
    View in: PubMed
    Score: 0.008
  101. Letter by Secemsky et al Regarding Article, "Relationship Between Femoral Vascular Closure Devices and Short-Term Mortality From 271?845 Percutaneous Coronary Intervention Procedures Performed in the United Kingdom Between 2006 and 2011: A Propensity Score-Corrected Analysis From the British Cardiovascular Intervention Society". Circ Cardiovasc Interv. 2016 09; 9(9).
    View in: PubMed
    Score: 0.008
  102. Contemporary Drug-Eluting Stent Platforms: Design, Safety, and Clinical Efficacy. Interv Cardiol Clin. 2016 07; 5(3):331-347.
    View in: PubMed
    Score: 0.008
  103. Incidence and predictors of incomplete revascularization in a contemporary cohort. Coron Artery Dis. 2016 May; 27(3):191-8.
    View in: PubMed
    Score: 0.008
  104. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016 Apr 26; 315(16):1735-49.
    View in: PubMed
    Score: 0.008
  105. Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention: An Instrumental Variable Analysis. Circ Cardiovasc Interv. 2016 Apr; 9(4):e003464.
    View in: PubMed
    Score: 0.008
  106. Management of Complications. Interv Cardiol Clin. 2016 04; 5(2):201-209.
    View in: PubMed
    Score: 0.008
  107. Letter by Wasfy et al Regarding Article, "Facility Level Variation in Hospitalization, Mortality, and Costs in the 30 Days After Percutaneous Coronary Intervention: Insights on Short-Term Healthcare Value From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System (VA CART) Program". Circulation. 2016 Feb 02; 133(5):e376.
    View in: PubMed
    Score: 0.008
  108. Future of the PCI Readmission Metric. Circ Cardiovasc Qual Outcomes. 2016 Mar; 9(2):186-9.
    View in: PubMed
    Score: 0.008
  109. Feasibility of a Tablet Computer System to Collect Patient-reported Symptom Severity in Patients Undergoing Diagnostic Coronary Angiography. Crit Pathw Cardiol. 2015 Dec; 14(4):139-45.
    View in: PubMed
    Score: 0.008
  110. Reply: Analysis of Dual Antiplatelet Therapy. J Am Coll Cardiol. 2015 Nov 03; 66(18):2056.
    View in: PubMed
    Score: 0.008
  111. Mortality risk with dual antiplatelet therapy? Lancet. 2015 Oct 17; 386(10003):1533-4.
    View in: PubMed
    Score: 0.008
  112. Angina Severity, Depression, and Response to Percutaneous Revascularization in Patients With Chronic Total Occlusion of Coronary Arteries. J Invasive Cardiol. 2016 Feb; 28(2):44-51.
    View in: PubMed
    Score: 0.008
  113. Predicting the Presence of an Acute Coronary Lesion Among Patients Resuscitated From Cardiac Arrest. Circ Cardiovasc Interv. 2015 Oct; 8(10).
    View in: PubMed
    Score: 0.007
  114. Response to Letter Regarding Article, "Surgical Ineligibility and Mortality Among Patients With Unprotected Left Main or Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention". Circulation. 2015 Sep 22; 132(12):e156.
    View in: PubMed
    Score: 0.007
  115. Reply: Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities. J Am Coll Cardiol. 2015 Sep 08; 66(10):1204-5.
    View in: PubMed
    Score: 0.007
  116. Enhancing the Prediction of 30-Day Readmission After Percutaneous Coronary Intervention Using Data Extracted by Querying of the Electronic Health Record. Circ Cardiovasc Qual Outcomes. 2015 Sep; 8(5):477-85.
    View in: PubMed
    Score: 0.007
  117. Assessing the optimal strategy for dual antiplatelet therapy. Expert Rev Cardiovasc Ther. 2015 Oct; 13(10):1067-9.
    View in: PubMed
    Score: 0.007
  118. Dual antiplatelet therapy duration and mortality - Authors' reply. Lancet. 2015 May 30; 385(9983):2149-50.
    View in: PubMed
    Score: 0.007
  119. Hospital variation in carotid stenting outcomes. JACC Cardiovasc Interv. 2015 May; 8(6):858-863.
    View in: PubMed
    Score: 0.007
  120. Public reporting in cardiovascular medicine: accountability, unintended consequences, and promise for improvement. Circulation. 2015 Apr 28; 131(17):1518-27.
    View in: PubMed
    Score: 0.007
  121. Proximal versus distal embolic protection for carotid artery stenting: a national cardiovascular data registry analysis. JACC Cardiovasc Interv. 2015 Apr 20; 8(4):609-15.
    View in: PubMed
    Score: 0.007
  122. Association between public reporting of outcomes with procedural management and mortality for patients with acute myocardial infarction. J Am Coll Cardiol. 2015 Mar 24; 65(11):1119-26.
    View in: PubMed
    Score: 0.007
  123. Close encounters with errors of the second kind: evaluating risks and benefits of long-term dual antiplatelet therapy. Eur Heart J. 2015 May 21; 36(20):1216-8.
    View in: PubMed
    Score: 0.007
  124. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015 May 26; 65(20):2211-21.
    View in: PubMed
    Score: 0.007
  125. Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected]. J Am Coll Cardiol. 2015 Mar 03; 65(8):787-790.
    View in: PubMed
    Score: 0.007
  126. Population trends in rates of coronary revascularization. JAMA Intern Med. 2015 Mar; 175(3):454-6.
    View in: PubMed
    Score: 0.007
  127. Evaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2015 Jan; 8(1):96-102.
    View in: PubMed
    Score: 0.007
  128. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet. 2015 Feb 28; 385(9970):792-8.
    View in: PubMed
    Score: 0.007
  129. Culprit only, multivessel, or staged multivessel intervention in STEMI: new insights or insurmountable methodologic obstacles? Catheter Cardiovasc Interv. 2014 Nov 15; 84(6):923-4.
    View in: PubMed
    Score: 0.007
  130. Surgical ineligibility and mortality among patients with unprotected left main or multivessel coronary artery disease undergoing percutaneous coronary intervention. Circulation. 2014 Dec 23; 130(25):2295-301.
    View in: PubMed
    Score: 0.007
  131. Public reporting and coronary revascularization: risk and benefit. Coron Artery Dis. 2014 Nov; 25(7):619-26.
    View in: PubMed
    Score: 0.007
  132. Clinical preventability of 30-day readmission after percutaneous coronary intervention. J Am Heart Assoc. 2014 Sep 26; 3(5):e001290.
    View in: PubMed
    Score: 0.007
  133. Blood transfusion in myocardial infarction: opening old wounds for comparative-effectiveness research. J Am Coll Cardiol. 2014 Aug 26; 64(8):820-2.
    View in: PubMed
    Score: 0.007
  134. Defining unavoidable delays in primary percutaneous coronary intervention: discordance among patients excluded from National Cardiovascular Quality Registries. J Am Heart Assoc. 2014 Jun 25; 3(3):e000944.
    View in: PubMed
    Score: 0.007
  135. Clinical prediction model suitable for assessing hospital quality for patients undergoing carotid endarterectomy. J Am Heart Assoc. 2014 Jun 17; 3(3):e000728.
    View in: PubMed
    Score: 0.007
  136. Association between operator procedure volume and patient outcomes in percutaneous coronary intervention: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2014 Jul; 7(4):560-6.
    View in: PubMed
    Score: 0.007
  137. Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable? Am Heart J. 2014 Jul; 168(1):103-9.
    View in: PubMed
    Score: 0.007
  138. Population trends from 2000-2011 in nuclear myocardial perfusion imaging use. JAMA. 2014 Mar 26; 311(12):1248-9.
    View in: PubMed
    Score: 0.007
  139. Reply: Bleeding after PCI, vascular access, and falsification endpoints in observational studies. J Am Coll Cardiol. 2014 Jun 17; 63(23):2587-2588.
    View in: PubMed
    Score: 0.007
  140. Cardiovascular event risk after noncardiac surgery. JAMA. 2014 Feb 05; 311(5):525.
    View in: PubMed
    Score: 0.007
  141. Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis and critical examination of current methodologies. Catheter Cardiovasc Interv. 2014 May 01; 83(6):975-83.
    View in: PubMed
    Score: 0.007
  142. Comparative effectiveness of commonly used devices for carotid artery stenting: an NCDR Analysis (National Cardiovascular Data Registry). JACC Cardiovasc Interv. 2014 Feb; 7(2):171-177.
    View in: PubMed
    Score: 0.007
  143. High-risk percutaneous coronary intervention in the era of public reporting: clinical and ethical considerations in the care of an elderly patient with critical left main disease and shock. Circulation. 2014 Jan 14; 129(2):258-65.
    View in: PubMed
    Score: 0.007
  144. Causes of short-term readmission after percutaneous coronary intervention. Circ Cardiovasc Interv. 2014 Feb; 7(1):97-103.
    View in: PubMed
    Score: 0.007
  145. Impact of academic year timing on percutaneous coronary intervention outcomes at training institutions. J Am Coll Cardiol. 2014 Mar 18; 63(10):1025-6.
    View in: PubMed
    Score: 0.007
  146. Instrumental variable analysis to compare effectiveness of stents in the extremely elderly. Circ Cardiovasc Qual Outcomes. 2014 Jan; 7(1):118-24.
    View in: PubMed
    Score: 0.007
  147. Reporting trends and outcomes in ST-segment-elevation myocardial infarction national hospital quality assessment programs. Circulation. 2014 Jan 14; 129(2):194-202.
    View in: PubMed
    Score: 0.007
  148. Comparison of transradial versus transfemoral percutaneous coronary intervention in routine practice: evidence for the importance of "falsification hypotheses" in observational studies of comparative effectiveness. J Am Coll Cardiol. 2013 Dec 03; 62(22):2147-8.
    View in: PubMed
    Score: 0.006
  149. A prediction model to identify patients at high risk for 30-day readmission after percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):429-35.
    View in: PubMed
    Score: 0.006
  150. Coronary chronic total occlusion in the elderly: demographic inevitability, treatment uncertainty. Catheter Cardiovasc Interv. 2013 Jul 01; 82(1):93-4.
    View in: PubMed
    Score: 0.006
  151. Risk-treatment paradox in the selection of transradial access for percutaneous coronary intervention. J Am Heart Assoc. 2013 May 24; 2(3):e000174.
    View in: PubMed
    Score: 0.006
  152. Pre-procedural risk quantification for carotid stenting using the CAS score: a report from the NCDR CARE Registry. J Am Coll Cardiol. 2012 Oct 23; 60(17):1617-22.
    View in: PubMed
    Score: 0.006
  153. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med. 2012 Aug 13; 172(15):1145-52.
    View in: PubMed
    Score: 0.006
  154. Another view of personalized medicine: optimizing stent selection on the basis of predicted benefit in percutaneous coronary intervention. Trends Cardiovasc Med. 2012 Jan; 22(1):23-8.
    View in: PubMed
    Score: 0.006
  155. Sources of hospital variation in short-term readmission rates after percutaneous coronary intervention. Circ Cardiovasc Interv. 2012 Apr; 5(2):227-36.
    View in: PubMed
    Score: 0.006
  156. Geographic disparities in the incidence and outcomes of hospitalized myocardial infarction: does a rising tide lift all boats? Circ Cardiovasc Qual Outcomes. 2012 Mar 01; 5(2):197-204.
    View in: PubMed
    Score: 0.006
  157. Choosing methods to minimize confounding in observational studies: do the ends justify the means? Circ Cardiovasc Qual Outcomes. 2011 Nov 01; 4(6):581-3.
    View in: PubMed
    Score: 0.006
  158. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention. Circulation. 2011 Oct 04; 124(14):1557-64.
    View in: PubMed
    Score: 0.006
  159. Accounting for the mortality benefit of drug-eluting stents in percutaneous coronary intervention: a comparison of methods in a retrospective cohort study. BMC Med. 2011 Jun 24; 9:78.
    View in: PubMed
    Score: 0.006
  160. Do postmarketing surveillance studies represent real-world populations? A comparison of patient characteristics and outcomes after carotid artery stenting. Circulation. 2011 Apr 05; 123(13):1384-90.
    View in: PubMed
    Score: 0.005
  161. Technical and procedural outcomes of the retrograde approach to chronic total occlusion interventions. EuroIntervention. 2020 12 04; 16(11):e891-e899.
    View in: PubMed
    Score: 0.005
  162. Takotsubo cardiomyopathy complicated by cardiac tamponade: classic hemodynamic findings with a new disease. Circulation. 2010 Sep 21; 122(12):1239-41.
    View in: PubMed
    Score: 0.005
  163. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010 Jun 10; 362(23):2155-65.
    View in: PubMed
    Score: 0.005
  164. Rethinking the epidemiology of acute myocardial infarction: challenges and opportunities. Arch Intern Med. 2010 May 10; 170(9):759-64.
    View in: PubMed
    Score: 0.005
  165. Anticoagulation with the direct thrombin inhibitor argatroban in patients presenting with acute coronary syndromes. Catheter Cardiovasc Interv. 2009 Aug 01; 74(2):359-64.
    View in: PubMed
    Score: 0.005
  166. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. Am J Cardiol. 2007 Dec 15; 100(12):1734-8.
    View in: PubMed
    Score: 0.004
  167. Predictors for the development of elevated anti-heparin/platelet factor 4 antibody titers in patients undergoing cardiac catheterization. Am J Cardiol. 2006 Aug 01; 98(3):419-21.
    View in: PubMed
    Score: 0.004
  168. Argatroban: update. Am Heart J. 2006 Jun; 151(6):1131-8.
    View in: PubMed
    Score: 0.004
  169. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus. Dis Esophagus. 2003; 16(3):193-8.
    View in: PubMed
    Score: 0.003
  170. Relation of the Number of Cardiovascular Conditions and Short-term Symptom Improvement After Percutaneous Coronary Intervention for Stable Angina Pectoris. Am J Cardiol. 2021 09 15; 155:1-8.
    View in: PubMed
    Score: 0.003
  171. New Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries [NCDR] Linked With All-Payer Claims). Am J Cardiol. 2021 07 15; 151:70-77.
    View in: PubMed
    Score: 0.003
  172. Racial and Ethnic Disparities in Heart and Cerebrovascular Disease Deaths During the COVID-19 Pandemic in the United States. Circulation. 2021 06 15; 143(24):2346-2354.
    View in: PubMed
    Score: 0.003
  173. Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65. J Cardiovasc Electrophysiol. 2021 06; 32(6):1529-1537.
    View in: PubMed
    Score: 0.003
  174. Rural-Urban Disparities: Diabetes, Hypertension, Heart Disease, and Stroke Mortality Among Black and White Adults, 1999-2018. J Am Coll Cardiol. 2021 03 23; 77(11):1480-1481.
    View in: PubMed
    Score: 0.003
  175. Association Between the Proportion of Black Patients Cared for at Hospitals and Financial Penalties Under Value-Based Payment Programs. JAMA. 2021 03 23; 325(12):1219-1221.
    View in: PubMed
    Score: 0.003
  176. Five-year clinical outcomes of zotarolimus-eluting stents in coronary total occlusions. EuroIntervention. 2021 Mar 19; 16(16):1326-1332.
    View in: PubMed
    Score: 0.003
  177. Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent. Circ Cardiovasc Interv. 2021 03; 14(3):e010144.
    View in: PubMed
    Score: 0.003
  178. Variations in the Course of the Carotid Arteries in Patients with Retropharyngeal Parathyroid Adenomas. AJNR Am J Neuroradiol. 2021 04; 42(4):749-752.
    View in: PubMed
    Score: 0.003
  179. Association Between County-Level Change in Economic Prosperity and Change in Cardiovascular Mortality Among Middle-aged US Adults. JAMA. 2021 02 02; 325(5):445-453.
    View in: PubMed
    Score: 0.003
  180. Rural-Urban Disparities In All-Cause Mortality Among Low-Income Medicare Beneficiaries, 2004-17. Health Aff (Millwood). 2021 02; 40(2):289-296.
    View in: PubMed
    Score: 0.003
  181. Rationale and Design of the SAFE-PAD Study. Circ Cardiovasc Qual Outcomes. 2021 01; 14(1):e007040.
    View in: PubMed
    Score: 0.003
  182. Health Care Utilization Following Inpatient Femoropopliteal Revascularization With Drug-Coated Balloon Angioplasty: A Nationwide Cohort Analysis. J Endovasc Ther. 2021 Apr; 28(2):246-254.
    View in: PubMed
    Score: 0.003
  183. Association of Acute Procedural Results With Long-Term Outcomes After CTO PCI. JACC Cardiovasc Interv. 2021 02 08; 14(3):278-288.
    View in: PubMed
    Score: 0.003
  184. Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy". Circulation. 2020 10 13; 142(15):e212-e213.
    View in: PubMed
    Score: 0.003
  185. Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States. J Am Coll Cardiol. 2020 09 29; 76(13):1521-1531.
    View in: PubMed
    Score: 0.003
  186. Medicaid Expansion and Ventricular Assist Device Implantation: An Analysis of the INTERMACS Registry. J Am Coll Cardiol. 2020 09 22; 76(12):1501-1502.
    View in: PubMed
    Score: 0.003
  187. Association Between 90-Minute Door-to-Balloon Time, Selective Exclusion of Myocardial Infarction Cases, and Access Site Choice: Insights From the Cardiac Care Outcomes Assessment Program (COAP) in Washington State. Circ Cardiovasc Interv. 2020 09; 13(9):e009179.
    View in: PubMed
    Score: 0.003
  188. Outcomes of retrograde chronic total occlusion percutaneous coronary intervention: A report from the OPEN-CTO registry. Catheter Cardiovasc Interv. 2021 05 01; 97(6):1162-1173.
    View in: PubMed
    Score: 0.003
  189. Community-Level Factors Associated With Racial And Ethnic Disparities In COVID-19 Rates In Massachusetts. Health Aff (Millwood). 2020 11; 39(11):1984-1992.
    View in: PubMed
    Score: 0.003
  190. Incidence, Prediction, and Causes of Unplanned 30-Day Hospital Admission After Ambulatory Procedures. Anesth Analg. 2020 08; 131(2):497-507.
    View in: PubMed
    Score: 0.003
  191. Performance of Hospitals When Assessing Disease-Based Mortality Compared With Procedural Mortality for Patients With Acute Myocardial Infarction. JAMA Cardiol. 2020 07 01; 5(7):765-772.
    View in: PubMed
    Score: 0.003
  192. Equipment utilization in chronic total occlusion percutaneous coronary interventions: Insights from the PROGRESS-CTO registry. Catheter Cardiovasc Interv. 2021 03; 97(4):658-667.
    View in: PubMed
    Score: 0.003
  193. Association of Homelessness with Hospital Readmissions-an Analysis of Three Large States. J Gen Intern Med. 2020 09; 35(9):2576-2583.
    View in: PubMed
    Score: 0.003
  194. Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement: Variation in Practice and Outcomes. JACC Cardiovasc Interv. 2020 06 08; 13(11):1277-1287.
    View in: PubMed
    Score: 0.003
  195. Comparison of Reperfusion Strategies for ST-Segment-Elevation Myocardial Infarction: A Multivariate Network Meta-analysis. J Am Heart Assoc. 2020 06 16; 9(12):e015186.
    View in: PubMed
    Score: 0.003
  196. SCAI position statement on optimal percutaneous coronary interventional therapy for complex coronary artery disease. Catheter Cardiovasc Interv. 2020 08; 96(2):346-362.
    View in: PubMed
    Score: 0.003
  197. Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs. JAMA. 2020 Jun 02; 323(21):2192-2195.
    View in: PubMed
    Score: 0.003
  198. Performance in Federal Value-Based Programs of Hospitals Recognized by the American Heart Association and American College of Cardiology for High-Quality Heart Failure and Acute Myocardial Infarction Care. JAMA Cardiol. 2020 05 01; 5(5):515-521.
    View in: PubMed
    Score: 0.003
  199. Multidisciplinary Heart Team Approach for Complex Coronary Artery Disease: Single Center Clinical Presentation. J Am Heart Assoc. 2020 04 21; 9(8):e014738.
    View in: PubMed
    Score: 0.003
  200. Trends and predictors of early ablation for Atrial Fibrillation in a Nationwide population under age 65: a retrospective observational study. BMC Cardiovasc Disord. 2020 04 06; 20(1):161.
    View in: PubMed
    Score: 0.003
  201. Database Inaccuracies and Disparities in Care Among Homeless Adults Hospitalized for Cardiovascular Conditions-Reply. JAMA Intern Med. 2020 04 01; 180(4):614-615.
    View in: PubMed
    Score: 0.003
  202. Association of Outpatient Practice-Level Socioeconomic Disadvantage With Quality of Care and Outcomes Among Older Adults With Coronary Artery Disease: Implications for Value-Based Payment. Circ Cardiovasc Qual Outcomes. 2020 04; 13(4):e005977.
    View in: PubMed
    Score: 0.003
  203. Temporal Trends in Chronic Total Occlusion Percutaneous Coronary Interventions: Insights From the PROGRESS-CTO Registry. J Invasive Cardiol. 2020 Apr; 32(4):153-160.
    View in: PubMed
    Score: 0.003
  204. AF Ablation Outcomes: Real World or Fun House Mirror? J Am Coll Cardiol. 2020 03 17; 75(10):1243.
    View in: PubMed
    Score: 0.003
  205. Mortality and Hospitalizations for Dually Enrolled and Nondually Enrolled Medicare Beneficiaries Aged 65 Years or Older, 2004 to 2017. JAMA. 2020 03 10; 323(10):961-969.
    View in: PubMed
    Score: 0.003
  206. Disparities in Care and Mortality Among Homeless Adults Hospitalized for Cardiovascular Conditions. JAMA Intern Med. 2020 03 01; 180(3):357-366.
    View in: PubMed
    Score: 0.003
  207. Retrograde Chronic Total Occlusion Percutaneous Coronary Intervention via Saphenous Vein Graft. JACC Cardiovasc Interv. 2020 02 24; 13(4):517-526.
    View in: PubMed
    Score: 0.003
  208. Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada. J Thorac Cardiovasc Surg. 2021 Aug; 162(2):616-624.e3.
    View in: PubMed
    Score: 0.003
  209. Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. J Am Heart Assoc. 2020 02 18; 9(4):e013606.
    View in: PubMed
    Score: 0.003
  210. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation. 2020 04 14; 141(15):1214-1224.
    View in: PubMed
    Score: 0.003
  211. Suitability of elderly adult hospital readmission rates for profiling readmissions in younger adult and pediatric populations. Health Serv Res. 2020 04; 55(2):277-287.
    View in: PubMed
    Score: 0.003
  212. Relation of Frailty to Outcomes After Catheter Ablation of Atrial Fibrillation. Am J Cardiol. 2020 05 01; 125(9):1317-1323.
    View in: PubMed
    Score: 0.003
  213. Association between procedure appropriateness and patient-reported outcomes after percutaneous coronary intervention. Heart. 2020 03; 106(6):441-446.
    View in: PubMed
    Score: 0.003
  214. The Impact of Peripheral Artery Disease in Chronic Total Occlusion Percutaneous Coronary Intervention (Insights From PROGRESS-CTO Registry). Angiology. 2020 03; 71(3):274-280.
    View in: PubMed
    Score: 0.003
  215. Readmissions after acute type B aortic dissection. J Vasc Surg. 2020 07; 72(1):73-83.e2.
    View in: PubMed
    Score: 0.003
  216. Utilization and Outcomes of Thrombolytic Therapy for Acute Pulmonary Embolism: A Nationwide Cohort Study. Chest. 2020 03; 157(3):645-653.
    View in: PubMed
    Score: 0.002
  217. A Need For Long-Term Results of LMCA-CTO-PCI. J Invasive Cardiol. 2019 11; 31(11):E342.
    View in: PubMed
    Score: 0.002
  218. Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study). Am J Cardiol. 2019 12 15; 124(12):1813-1820.
    View in: PubMed
    Score: 0.002
  219. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019 08 14; 40(31):2632-2653.
    View in: PubMed
    Score: 0.002
  220. Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. Circulation. 2019 07 30; 140(5):420-433.
    View in: PubMed
    Score: 0.002
  221. Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry. Am Heart J. 2019 10; 216:53-61.
    View in: PubMed
    Score: 0.002
  222. Impact of concomitant treatment of non-chronic total occlusion lesions at the time of chronic total occlusion intervention. Int J Cardiol. 2020 01 15; 299:75-80.
    View in: PubMed
    Score: 0.002
  223. Association of Medicaid Expansion With Cardiovascular Mortality. JAMA Cardiol. 2019 07 01; 4(7):671-679.
    View in: PubMed
    Score: 0.002
  224. Left Main Chronic Total Occlusion Percutaneous Coronary Intervention: A Case Series. J Invasive Cardiol. 2019 Jul; 31(7):E220-E225.
    View in: PubMed
    Score: 0.002
  225. Intensive care use and mortality among patients with ST elevation myocardial infarction: retrospective cohort study. BMJ. 2019 06 04; 365:l1927.
    View in: PubMed
    Score: 0.002
  226. Etiologies, trends, and predictors of readmission in ST-elevation myocardial infarction patients undergoing multivessel percutaneous coronary intervention. Catheter Cardiovasc Interv. 2019 Dec 01; 94(7):905-914.
    View in: PubMed
    Score: 0.002
  227. Uptake of Drug-Eluting Bioresorbable Vascular Scaffolds in Clinical Practice: An NCDR Registry to Practice Project. JAMA Cardiol. 2019 06 01; 4(6):564-568.
    View in: PubMed
    Score: 0.002
  228. Landscape of Cardiovascular Device Registries in the United States. J Am Heart Assoc. 2019 06 04; 8(11):e012756.
    View in: PubMed
    Score: 0.002
  229. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation. 2019 07 16; 140(3):240-261.
    View in: PubMed
    Score: 0.002
  230. The Hospital Readmissions Reduction Program - Time for a Reboot. N Engl J Med. 2019 Jun 13; 380(24):2289-2291.
    View in: PubMed
    Score: 0.002
  231. Hospital-Specific Mortality for Acute Myocardial Infarction Versus Emergency Percutaneous Coronary Intervention in New York State. JACC Cardiovasc Interv. 2019 05 13; 12(9):898-899.
    View in: PubMed
    Score: 0.002
  232. Effect of Public Reporting on the Utilization of Coronary Angiography After Out-of-Hospital Cardiac Arrest. Circ Cardiovasc Interv. 2019 04; 12(4):e007564.
    View in: PubMed
    Score: 0.002
  233. In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Interventions in Patients With Prior Coronary Artery Bypass Graft Surgery. Circ Cardiovasc Interv. 2019 03; 12(3):e007338.
    View in: PubMed
    Score: 0.002
  234. Procedural Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions Via the Radial Approach: Insights From an International Chronic Total Occlusion Registry. JACC Cardiovasc Interv. 2019 02 25; 12(4):346-358.
    View in: PubMed
    Score: 0.002
  235. Usefulness of Atherectomy in Chronic Total Occlusion Interventions (from the PROGRESS-CTO Registry). Am J Cardiol. 2019 05 01; 123(9):1422-1428.
    View in: PubMed
    Score: 0.002
  236. Association of State Medicaid Expansion With Quality of Care and Outcomes for Low-Income Patients Hospitalized With Acute Myocardial Infarction. JAMA Cardiol. 2019 02 01; 4(2):120-127.
    View in: PubMed
    Score: 0.002
  237. Frequency and Outcomes of Ad Hoc Versus Planned Chronic Total Occlusion Percutaneous Coronary Intervention: Multicenter Experience. J Invasive Cardiol. 2019 May; 31(5):133-139.
    View in: PubMed
    Score: 0.002
  238. Treating Symptomatic Aortic Stenosis With Transcatheter Aortic Valve Replacement: Is There Time to Wait? J Am Heart Assoc. 2019 01 08; 8(1):e011527.
    View in: PubMed
    Score: 0.002
  239. Trends, Causes, and Outcomes of Hospitalizations for Homeless Individuals: A Retrospective Cohort Study. Med Care. 2019 01; 57(1):21-27.
    View in: PubMed
    Score: 0.002
  240. Comparison Between Traditional and Guide-Catheter Extension Reverse Controlled Antegrade Dissection and Retrograde Tracking: Insights From the PROGRESS-CTO Registry. J Invasive Cardiol. 2019 01; 31(1):27-34.
    View in: PubMed
    Score: 0.002
  241. Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy. PLoS One. 2018; 13(10):e0205457.
    View in: PubMed
    Score: 0.002
  242. In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease. J Invasive Cardiol. 2018 11; 30(11):E113-E121.
    View in: PubMed
    Score: 0.002
  243. Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. Am Heart J. 2018 11; 205:110-117.
    View in: PubMed
    Score: 0.002
  244. Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women. Circ Cardiovasc Interv. 2018 08; 11(8):e005308.
    View in: PubMed
    Score: 0.002
  245. Prevalence and Outcomes of Percutaneous Coronary Interventions for Ostial Chronic Total Occlusions: Insights From a Multicenter Chronic Total Occlusion Registry. Can J Cardiol. 2018 10; 34(10):1264-1274.
    View in: PubMed
    Score: 0.002
  246. Public Reporting of Percutaneous Coronary Intervention Outcomes: Moving Beyond the Status Quo. JAMA Cardiol. 2018 07 01; 3(7):635-640.
    View in: PubMed
    Score: 0.002
  247. Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. Catheter Cardiovasc Interv. 2018 11 01; 92(5):E348-E355.
    View in: PubMed
    Score: 0.002
  248. In-hospital Outcomes of Attempting More Than One Chronic Total Coronary Occlusion Through Percutaneous Intervention During the Same Procedure. Am J Cardiol. 2018 08 01; 122(3):381-387.
    View in: PubMed
    Score: 0.002
  249. The Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: Update From the PROGRESS CTO Registry. JACC Cardiovasc Interv. 2018 07 23; 11(14):1325-1335.
    View in: PubMed
    Score: 0.002
  250. Acute Myocardial Infarction Mortality During Dates of National Interventional Cardiology Meetings. J Am Heart Assoc. 2018 03 09; 7(6).
    View in: PubMed
    Score: 0.002
  251. Mechanical Circulatory Support in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Multicenter U.S. Registry. J Invasive Cardiol. 2018 03; 30(3):81-87.
    View in: PubMed
    Score: 0.002
  252. Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis. Circ Cardiovasc Interv. 2018 01; 11(1):e005795.
    View in: PubMed
    Score: 0.002
  253. Personal and Professional Characteristics of U.S. Dual-Boarded Critical Care Cardiologists in 2015. Crit Care Med. 2017 Dec; 45(12):e1292-e1296.
    View in: PubMed
    Score: 0.002
  254. Retrograde CTO-PCI of Native Coronary Arteries Via Left Internal Mammary Artery Grafts: Insights From a Multicenter U.S. Registry. J Invasive Cardiol. 2018 03; 30(3):89-96.
    View in: PubMed
    Score: 0.002
  255. Variation in the Adoption of Transradial Access for ST-Segment Elevation Myocardial Infarction: Insights From the NCDR CathPCI Registry. JACC Cardiovasc Interv. 2017 11 27; 10(22):2242-2254.
    View in: PubMed
    Score: 0.002
  256. Current Perspectives and Practices on Chronic Total Occlusion Percutaneous Coronary Interventions. J Invasive Cardiol. 2018 02; 30(2):43-50.
    View in: PubMed
    Score: 0.002
  257. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. Am Heart J. 2018 01; 195:151-152.
    View in: PubMed
    Score: 0.002
  258. Residual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.002
  259. Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty: A Report From the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures). JACC Cardiovasc Interv. 2017 08 14; 10(15):1523-1534.
    View in: PubMed
    Score: 0.002
  260. Reply: Duration of the Double Antiplatelet Therapy in Patients With Coronary and Peripheral Arterial Disease: The Key Might Be in the Type of Drug. JACC Cardiovasc Interv. 2017 07 24; 10(14):1468-1469.
    View in: PubMed
    Score: 0.002
  261. Incidence, Treatment, and Outcomes of Coronary Perforation During Chronic Total Occlusion Percutaneous Coronary Intervention. Am J Cardiol. 2017 Oct 15; 120(8):1285-1292.
    View in: PubMed
    Score: 0.002
  262. Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial. JAMA Cardiol. 2017 06 01; 2(6):673-677.
    View in: PubMed
    Score: 0.002
  263. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2017 06 12; 10(11):1102-1111.
    View in: PubMed
    Score: 0.002
  264. The Impact of Proximal Vessel Tortuosity on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. J Invasive Cardiol. 2017 Aug; 29(8):264-270.
    View in: PubMed
    Score: 0.002
  265. Novel Method for Exchange of Impella Circulatory Assist Catheter: The "Trojan Horse" Technique. J Invasive Cardiol. 2017 Jul; 29(7):250-252.
    View in: PubMed
    Score: 0.002
  266. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. JACC Cardiovasc Interv. 2017 05 08; 10(9):942-954.
    View in: PubMed
    Score: 0.002
  267. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol. 2017 05 01; 2(5):478-487.
    View in: PubMed
    Score: 0.002
  268. Impact of Calcium on Chronic Total Occlusion Percutaneous Coronary Interventions. Am J Cardiol. 2017 07 01; 120(1):40-46.
    View in: PubMed
    Score: 0.002
  269. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation. 2017 May 02; 135(18):1720-1732.
    View in: PubMed
    Score: 0.002
  270. Time-Course of Cause-Specific Hospital Admissions During Snowstorms: An Analysis of Electronic Medical Records From Major Hospitals in Boston, Massachusetts. Am J Epidemiol. 2017 02 15; 185(4):283-294.
    View in: PubMed
    Score: 0.002
  271. Sex Differences in Faculty Rank Among Academic Cardiologists in the United States. Circulation. 2017 02 07; 135(6):506-517.
    View in: PubMed
    Score: 0.002
  272. The Impact of Age and Sex on In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention. J Invasive Cardiol. 2017 Apr; 29(4):116-122.
    View in: PubMed
    Score: 0.002
  273. Approaches to percutaneous coronary intervention of right coronary artery chronic total occlusions: insights from a multicentre US registry. EuroIntervention. 2016 Dec 10; 12(11):e1326-e1335.
    View in: PubMed
    Score: 0.002
  274. Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score. Thromb Haemost. 2017 01 26; 117(2):246-251.
    View in: PubMed
    Score: 0.002
  275. Predictors of Excess Patient Radiation Exposure During Chronic Total Occlusion Coronary Intervention: Insights From a Contemporary Multicentre Registry. Can J Cardiol. 2017 04; 33(4):478-484.
    View in: PubMed
    Score: 0.002
  276. 2016 Revision of the SCAI position statement on public reporting. Catheter Cardiovasc Interv. 2017 Feb 01; 89(2):269-279.
    View in: PubMed
    Score: 0.002
  277. Coronary artery spatial distribution of chronic total occlusions: Insights from a large US registry. Catheter Cardiovasc Interv. 2017 Jul; 90(1):23-30.
    View in: PubMed
    Score: 0.002
  278. Impact of diabetes mellitus on acute outcomes of percutaneous coronary intervention in chronic total occlusions: insights from a US multicentre registry. Diabet Med. 2017 04; 34(4):558-562.
    View in: PubMed
    Score: 0.002
  279. Implications of Public Reporting of Risk-Adjusted Mortality Following Percutaneous Coronary Intervention: Misperceptions and Potential Consequences for High-Risk Patients Including Nonsurgical Patients. JACC Cardiovasc Interv. 2016 10 24; 9(20):2077-2085.
    View in: PubMed
    Score: 0.002
  280. Development and Validation of a Scoring System for Predicting Periprocedural Complications During Percutaneous Coronary Interventions of Chronic Total Occlusions: The Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS CTO) Complications Score. J Am Heart Assoc. 2016 10 11; 5(10).
    View in: PubMed
    Score: 0.002
  281. Impact of Proximal Cap Ambiguity on Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Multicenter US Registry. J Invasive Cardiol. 2016 Oct; 28(10):391-396.
    View in: PubMed
    Score: 0.002
  282. Real-time fusion of coronary CT angiography with x-ray fluoroscopy during chronic total occlusion PCI. Eur Radiol. 2017 Jun; 27(6):2464-2473.
    View in: PubMed
    Score: 0.002
  283. Prevalence, indications and management of balloon uncrossable chronic total occlusions: Insights from a contemporary multicenter US registry. Catheter Cardiovasc Interv. 2017 Jul; 90(1):12-20.
    View in: PubMed
    Score: 0.002
  284. Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention. JAMA Cardiol. 2016 Sep 01; 1(6):655-65.
    View in: PubMed
    Score: 0.002
  285. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. Circulation. 2016 Oct 04; 134(14):989-998.
    View in: PubMed
    Score: 0.002
  286. Clinical Interventions to Reduce Preventable Hospital Readmission After Percutaneous Coronary Intervention. Circ Cardiovasc Qual Outcomes. 2016 09; 9(5):600-4.
    View in: PubMed
    Score: 0.002
  287. Comparison of various scores for predicting success of chronic total occlusion percutaneous coronary intervention. Int J Cardiol. 2016 Dec 01; 224:50-56.
    View in: PubMed
    Score: 0.002
  288. Use of Intravascular Imaging During Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. J Am Heart Assoc. 2016 08 20; 5(8).
    View in: PubMed
    Score: 0.002
  289. Contrast Utilization During Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. J Invasive Cardiol. 2016 Jul; 28(7):288-94.
    View in: PubMed
    Score: 0.002
  290. National Trends in Hospitalizations of Adults With Tetralogy of Fallot. Am J Cardiol. 2016 09 15; 118(6):906-911.
    View in: PubMed
    Score: 0.002
  291. Is multivessel intervention in ST-elevation myocardial infarction associated with early harm? Insights from observational data. Catheter Cardiovasc Interv. 2016 Nov; 88(5):697-707.
    View in: PubMed
    Score: 0.002
  292. Outcomes With the Use of the Retrograde Approach for Coronary Chronic Total Occlusion Interventions in a Contemporary Multicenter US Registry. Circ Cardiovasc Interv. 2016 06; 9(6).
    View in: PubMed
    Score: 0.002
  293. Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention. Am Heart J. 2016 08; 178:190-7.
    View in: PubMed
    Score: 0.002
  294. Guidewire and microcatheter utilization patterns during antegrade wire escalation in chronic total occlusion percutaneous coronary intervention: Insights from a contemporary multicenter registry. Catheter Cardiovasc Interv. 2017 Mar 01; 89(4):E90-E98.
    View in: PubMed
    Score: 0.002
  295. Effect of Lesion Age on Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary US Multicenter Registry. Can J Cardiol. 2016 12; 32(12):1433-1439.
    View in: PubMed
    Score: 0.002
  296. Use of antegrade dissection re-entry in coronary chronic total occlusion percutaneous coronary intervention in a contemporary multicenter registry. Int J Cardiol. 2016 Jul 01; 214:428-37.
    View in: PubMed
    Score: 0.002
  297. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol. 2016 May 31; 67(21):2492-502.
    View in: PubMed
    Score: 0.002
  298. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation. 2016 May 03; 133(18):1772-82.
    View in: PubMed
    Score: 0.002
  299. Editorial Commentary: Hard questions for mobile technology in cardiology. Trends Cardiovasc Med. 2016 May; 26(4):387-8.
    View in: PubMed
    Score: 0.002
  300. Effect of Previous Failure on Subsequent Procedural Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention (from a Contemporary Multicenter Registry). Am J Cardiol. 2016 Apr 15; 117(8):1267-71.
    View in: PubMed
    Score: 0.002
  301. Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26; 133(4):447-54.
    View in: PubMed
    Score: 0.002
  302. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. JACC Cardiovasc Interv. 2016 Jan 25; 9(2):138-47.
    View in: PubMed
    Score: 0.002
  303. Development and Validation of a Novel Scoring System for Predicting Technical Success of Chronic Total Occlusion Percutaneous Coronary Interventions: The PROGRESS CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) Score. JACC Cardiovasc Interv. 2016 Jan 11; 9(1):1-9.
    View in: PubMed
    Score: 0.002
  304. Coronary CT angiography for myocardial infarction: case studies of the Massachusetts General Hospital. Coron Artery Dis. 2016 Jan; 27(1):72-3.
    View in: PubMed
    Score: 0.002
  305. Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease. Curr Atheroscler Rep. 2016 Jan; 18(1):5.
    View in: PubMed
    Score: 0.002
  306. Transradial Versus Transfemoral Access in Patients Undergoing Rescue Percutaneous Coronary Intervention After Fibrinolytic Therapy. JACC Cardiovasc Interv. 2015 Dec 21; 8(14):1868-76.
    View in: PubMed
    Score: 0.002
  307. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26; 133(4):e38-360.
    View in: PubMed
    Score: 0.002
  308. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J. 2016 Jan 21; 37(4):378-85.
    View in: PubMed
    Score: 0.002
  309. Differences Among Cardiologists in Rates of Positive Coronary Angiograms. J Am Heart Assoc. 2015 Oct 16; 4(10):e002393.
    View in: PubMed
    Score: 0.002
  310. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. JACC Cardiovasc Interv. 2015 Oct; 8(12):1552-62.
    View in: PubMed
    Score: 0.002
  311. Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device: A Systematic Review of Published Reports and Analytic Review of the FDA MAUDE Database. JAMA Intern Med. 2015 Jul; 175(7):1104-9.
    View in: PubMed
    Score: 0.002
  312. Clinical Utility of the Japan-Chronic Total Occlusion Score in Coronary Chronic Total Occlusion Interventions: Results from a Multicenter Registry. Circ Cardiovasc Interv. 2015 Jul; 8(7):e002171.
    View in: PubMed
    Score: 0.002
  313. Application and outcomes of a hybrid approach to chronic total occlusion percutaneous coronary intervention in a contemporary multicenter US registry. Int J Cardiol. 2015 Nov 01; 198:222-8.
    View in: PubMed
    Score: 0.002
  314. National Trends in Hospitalizations for Patients With Single-Ventricle Anatomy. Am J Cardiol. 2015 Sep 01; 116(5):773-8.
    View in: PubMed
    Score: 0.002
  315. Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015 Sep 01; 116(5):686-93.
    View in: PubMed
    Score: 0.002
  316. Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis. Heart. 2015 Oct; 101(20):1631-8.
    View in: PubMed
    Score: 0.002
  317. Standardized Outcome Measurement for Patients With Coronary Artery Disease: Consensus From the International Consortium for Health Outcomes Measurement (ICHOM). J Am Heart Assoc. 2015 May 19; 4(5).
    View in: PubMed
    Score: 0.002
  318. Duration of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2015 04 02; 372(14):1373-4.
    View in: PubMed
    Score: 0.002
  319. Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from Pooled PROTECT Trials). Am J Cardiol. 2015 Jun 15; 115(12):1678-84.
    View in: PubMed
    Score: 0.002
  320. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA. 2015 Mar 17; 313(11):1113-21.
    View in: PubMed
    Score: 0.002
  321. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015 Jan 27; 131(4):e29-322.
    View in: PubMed
    Score: 0.002
  322. The data extraction and longitudinal trend analysis network study of distributed automated postmarket cardiovascular device safety surveillance. Circ Cardiovasc Qual Outcomes. 2015 Jan; 8(1):38-46.
    View in: PubMed
    Score: 0.002
  323. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 04; 371(23):2155-66.
    View in: PubMed
    Score: 0.002
  324. Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. Am Heart J. 2015 Feb; 169(2):222-233.e5.
    View in: PubMed
    Score: 0.002
  325. The challenges of success: maintaining access to high-quality percutaneous coronary intervention in the face of declining procedural volumes. Circulation. 2014 Oct 14; 130(16):1343-5.
    View in: PubMed
    Score: 0.002
  326. Public reporting of PCI outcomes: for better or for worse. Curr Cardiol Rep. 2014 Jul; 16(7):500.
    View in: PubMed
    Score: 0.002
  327. Usefulness of postmarket studies to evaluate long-term safety of coronary eluting stents (from the ENDEAVOR and PROTECT Programs). Am J Cardiol. 2014 Aug 15; 114(4):528-33.
    View in: PubMed
    Score: 0.002
  328. Adherence to dual antiplatelet therapy after coronary stenting: a systematic review. Clin Cardiol. 2014 Aug; 37(8):505-13.
    View in: PubMed
    Score: 0.002
  329. Risk adjustment of ischemic stroke outcomes for comparing hospital performance: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Mar; 45(3):918-44.
    View in: PubMed
    Score: 0.002
  330. Usefulness of the Seattle Heart Failure Model to identify adults with congenital heart disease at high risk of poor outcome. Am J Cardiol. 2014 Mar 01; 113(5):865-70.
    View in: PubMed
    Score: 0.002
  331. A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. J Am Heart Assoc. 2013 Dec 05; 2(6):e000542.
    View in: PubMed
    Score: 0.002
  332. Procedural variation in the performance of primary percutaneous coronary intervention for ST-elevation myocardial infarction: a SCAI-based survey study of US interventional cardiologists. Catheter Cardiovasc Interv. 2014 Apr 01; 83(5):721-6.
    View in: PubMed
    Score: 0.002
  333. Unprotected carotid artery stenting in modern practice. Catheter Cardiovasc Interv. 2014 Mar 01; 83(4):595-602.
    View in: PubMed
    Score: 0.002
  334. Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study). Am J Cardiol. 2014 Apr 01; 113(7):1146-52.
    View in: PubMed
    Score: 0.002
  335. Cardiovascular care facts: a report from the national cardiovascular data registry: 2011. J Am Coll Cardiol. 2013 Nov 19; 62(21):1931-1947.
    View in: PubMed
    Score: 0.002
  336. Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis. Clin J Am Soc Nephrol. 2013 Dec; 8(12):2213-20.
    View in: PubMed
    Score: 0.002
  337. Features of coronary plaque in patients with metabolic syndrome and diabetes mellitus assessed by 3-vessel optical coherence tomography. Circ Cardiovasc Imaging. 2013 Sep; 6(5):665-73.
    View in: PubMed
    Score: 0.002
  338. A combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol. 2013 Jul; 24(8):1330-8.
    View in: PubMed
    Score: 0.002
  339. Caesarian dissection: a case of chest pain and dyspnea during delivery. Circulation. 2013 Apr 09; 127(14):1530-5.
    View in: PubMed
    Score: 0.002
  340. Hemorrhagic and ischemic outcomes after bivalirudin versus unfractionated heparin during carotid artery stenting: a propensity score analysis from the NCDR. Circ Cardiovasc Interv. 2013 Apr; 6(2):131-8.
    View in: PubMed
    Score: 0.002
  341. Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol. 2013 May 28; 61(21):2130-8.
    View in: PubMed
    Score: 0.002
  342. Model feedback in Bayesian propensity score estimation. Biometrics. 2013 Mar; 69(1):263-73.
    View in: PubMed
    Score: 0.002
  343. Risk prediction for adverse events after carotid artery stenting in higher surgical risk patients. Stroke. 2012 Dec; 43(12):3218-24.
    View in: PubMed
    Score: 0.002
  344. Comparison of nonculprit coronary plaque characteristics between patients with and without diabetes: a 3-vessel optical coherence tomography study. JACC Cardiovasc Interv. 2012 Nov; 5(11):1150-8.
    View in: PubMed
    Score: 0.002
  345. Management strategy in 249 consecutive patients with obstructive hypertrophic cardiomyopathy referred to a dedicated program. Am J Cardiol. 2012 Oct 15; 110(8):1169-74.
    View in: PubMed
    Score: 0.001
  346. Comparison of incidence and time course of neoatherosclerosis between bare metal stents and drug-eluting stents using optical coherence tomography. Am J Cardiol. 2012 Oct 01; 110(7):933-9.
    View in: PubMed
    Score: 0.001
  347. Association between leukocyte telomere length and drug-eluting stent strut coverage by optical coherence tomography. J Am Coll Cardiol. 2012 Jun 12; 59(24):2218-9.
    View in: PubMed
    Score: 0.001
  348. Nonculprit plaques in patients with acute coronary syndromes have more vulnerable features compared with those with non-acute coronary syndromes: a 3-vessel optical coherence tomography study. Circ Cardiovasc Imaging. 2012 Jul; 5(4):433-40.
    View in: PubMed
    Score: 0.001
  349. Percutaneous coronary interventions without on-site cardiac surgical backup. N Engl J Med. 2012 May 10; 366(19):1814-23.
    View in: PubMed
    Score: 0.001
  350. Surgical candidacy and selection biases in nonemergent left main stenting: implications for observational studies. JACC Cardiovasc Interv. 2011 Sep; 4(9):1020-7.
    View in: PubMed
    Score: 0.001
  351. Clinical factors and echocardiographic techniques related to the presence, size, and location of acoustic windows for leadless cardiac pacing. Europace. 2011 Dec; 13(12):1760-5.
    View in: PubMed
    Score: 0.001
  352. Anticoagulant agents in acute coronary syndromes. Curr Probl Cardiol. 2011 Apr; 36(4):127-68.
    View in: PubMed
    Score: 0.001
  353. Clinical referral patterns for carotid artery stenting versus carotid endarterectomy: results from the Carotid Artery Revascularization and Endarterectomy Registry. Circ Cardiovasc Interv. 2011 Feb 01; 4(1):88-94.
    View in: PubMed
    Score: 0.001
  354. Inadvertent femoral endarterectomy: a complication from a suture-based vascular closure device. J Vasc Access. 2011 Jan-Mar; 12(1):71-2.
    View in: PubMed
    Score: 0.001
  355. Safety and efficacy of the argatroban therapy during the early post-cardiac surgery period. J Thromb Thrombolysis. 2010 Oct; 30(3):276-80.
    View in: PubMed
    Score: 0.001
  356. Antiplatelet agents in acute coronary syndromes. Curr Probl Cardiol. 2010 Mar; 35(3):123-70.
    View in: PubMed
    Score: 0.001
  357. Calcium-triggered short-coupled polymorphous ventricular tachycardia. Pacing Clin Electrophysiol. 2010 Jan; 33(1):117-22.
    View in: PubMed
    Score: 0.001
  358. Efficacy and safety of argatroban in patients with heparin induced thrombocytopenia undergoing endovascular intervention for peripheral arterial disease. Catheter Cardiovasc Interv. 2008 Jul 01; 72(1):116-20.
    View in: PubMed
    Score: 0.001
  359. What is the optimal anticoagulation level with argatroban during percutaneous coronary intervention? Blood Coagul Fibrinolysis. 2008 Jul; 19(5):401-4.
    View in: PubMed
    Score: 0.001
  360. Episodic ventricular pacing with intact atrioventricular nodal function in a DDDR device: what is the rhythm and how can it be prevented? Heart Rhythm. 2008 Jun; 5(6):897-8.
    View in: PubMed
    Score: 0.001
  361. Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chem Biol. 2007 Oct; 14(10):1152-62.
    View in: PubMed
    Score: 0.001
  362. Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome. J Thromb Thrombolysis. 2008 Apr; 25(2):214-8.
    View in: PubMed
    Score: 0.001
  363. Analysis of cardiac dimensions, mass and function in heart transplant recipients using 64-slice multi-detector computed tomography. J Heart Lung Transplant. 2007 May; 26(5):478-84.
    View in: PubMed
    Score: 0.001
  364. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg. 2007 Feb; 83(2):592-7.
    View in: PubMed
    Score: 0.001
  365. Comparison of sixty-four-slice multidetector computed tomographic coronary angiography to coronary angiography with intravascular ultrasound for the detection of transplant vasculopathy. Am J Cardiol. 2006 Oct 01; 98(7):877-84.
    View in: PubMed
    Score: 0.001
  366. Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization. Am Heart J. 2006 Aug; 152(2):290.e1-7.
    View in: PubMed
    Score: 0.001
  367. Purification and characterization of human lymphoblast N-acetylglucosamine-1-phosphotransferase. Glycobiology. 1992 Apr; 2(2):119-25.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.